Therapeutic Asset Ratings

137 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Everolimus Breast Neoplasms	Fudan University	P4	B (61)
LIDOCAINE Breast Neoplasms	Chinese University of Hong Kong	P4	B (61)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Breast Neoplasms	Medipol University	P4	B (60)
Imlunestrant Breast Neoplasms	Eli Lilly and Company	P3	B (60)
Irinotecan Breast Neoplasms	Wang Jiayu	P3	B (60)
Neratinib Breast Neoplasms	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
Patritumab Deruxtecan Breast Neoplasms	Merck Sharp & Dohme LLC	P3	B (60)
Pembrolizumab Breast Neoplasms	Merck Sharp & Dohme LLC	P3	B (60)
Lapatinib Breast Neoplasms	Deraya University	P3	B (59)
Trastuzumab Emtansine Breast Neoplasms	Pierre Fabre Pharma GmbH	P3	B (59)
(+)-VINCRISTINE Breast Neoplasms	Wang Jiayu	P3	B (59)
Artiss Breast Neoplasms	Mid and South Essex NHS Foundation Trust	P4	B (58)
Fibrin Sealant Breast Neoplasms	Mid and South Essex NHS Foundation Trust	P4	B (58)
Talzenna Breast Neoplasms	Pfizer	P3	B (58)
rc48-adc Breast Neoplasms	Pfizer	P2/3	B (58)
Denosumab Breast Neoplasms	Alliance for Clinical Trials in Oncology	P3	B (57)
Eflapegrastim Breast Neoplasms	Eunseong Medical Foundation Good GANG-AN HOSPITAL	P4	B (56)
T-Dxd Breast Neoplasms	Yan Xue	P4	B (56)
Trastuzumab Deruxtecan Breast Neoplasms	Merck Sharp & Dohme LLC	P3	B (56)
Utidelone Breast Neoplasms	Sun Yat-sen University	P3	B (56)
Metformin Breast Neoplasms	Katherine D. Crew	P2	B (56)
Tucatinib Breast Neoplasms	Merck Sharp & Dohme LLC	P2	CCC (55)
Nuvastatic Breast Neoplasms	Natureceuticals Sdn Bhd	P3	CCC (54)
DEXAMETHASONE Breast Neoplasms	Brown University	P2	CCC (54)
Durvalumab Breast Neoplasms	Institute of Cancer Research, United Kingdom	P2	CCC (54)

Showing 26 to 50 of 137 assets

PreviousPage 2 of 6Next